Stilbenoid Oligomers: Documented Pharmacological Activities

Resveratrol oligomers — dimers, trimers, and tetramers formed by oxidative coupling of the stilbene monomer — have been evaluated across a broad range of in vitro and in vivo pharmacological assays. The following summary is limited to quantified results from peer-reviewed studies on the five compounds most commonly used as analytical reference standards: ε-viniferin, δ-viniferin, α-viniferin, vitisin A, and vitisin B.

Antioxidant assays

ε-Viniferin. In a comparative DPPH assay using equimolar compound concentrations, ε-viniferin achieved an IC₅₀ of ~80 µM — comparable to resveratrol itself (IC₅₀ ~82 µM) and within the 52–92 µM range reported across three independent studies (Sy et al., Molecules, 2023, 28, 7521). In the ferric reducing antioxidant power (FRAP) assay, ε-viniferin showed approximately double the activity of resveratrol (IC₅₀ ~28.8 µM). Both trans and cis isomers were evaluated for hydroxyl radical scavenging using a Fenton-type reaction system: trans-ε-viniferin significantly inhibited 2-deoxyribose degradation and rat-liver microsomal lipid peroxidation, while the cis isomer showed only moderate activity.

δ-Viniferin. The 3–8′ regioisomer displayed moderate DPPH scavenging and hydroxyl radical quenching activity in erythrocyte protection assays, where it reduced hemoglobin oxidation in human red blood cells exposed to oxidative stress.

α-Viniferin. The cyclotrimer showed activity across cupric ion-reducing antioxidant capacity (CUPRAC), FRAP, DPPH, and PTIO radical-scavenging assays. The mechanism involves both redox-mediated electron and H⁺-transfer and non-redox Fe²⁺-chelation.

Anti-inflammatory activity

Multiple compounds in this family have been evaluated in lipopolysaccharide (LPS)-stimulated macrophage models with quantified molecular endpoints.

α-Viniferin. In LPS-stimulated RAW 264.7 cells, α-viniferin suppressed COX-2 expression and prostaglandin E₂ (PGE₂) production in a dose-dependent manner, paralleled by effective inhibition of NF-κB transcriptional activity (Ha et al., 2018). The compound showed selective COX-2 inhibition with minimal activity against COX-1 (Chung et al., Planta Med., 2003, 69, 710–714). Oral administration at >30 mg/kg and intravenous administration at >3 mg/kg significantly attenuated carrageenan-induced paw edema in mice. In interferon-γ-stimulated macrophages, α-viniferin suppressed ERK-mediated STAT-1 activation, downregulating STAT-1-dependent inflammatory gene expression (Chung et al., J. Pharmacol. Sci., 2010, 112, 405–414). Dual regulation of the PI3K/Akt → NF-κB pathway and the Nrf2 → heme oxygenase-1 pathway has been demonstrated in microglial cells (Wu et al., 2020).

δ-Viniferin. In LPS-stimulated RAW 264.7 macrophages, δ-viniferin significantly suppressed iNOS, COX-2, and phosphorylated IκBα expression, with corresponding reductions in nitric oxide production. Mechanistic work showed blockade of PI3K and Akt phosphorylation, contributing to NF-κB signaling downregulation (Hsieh, 2016).

Vitisin A. The resveratrol tetramer suppressed LPS-induced NO production in RAW 264.7 cells via inhibition of ERK1/2 and p38 phosphorylation and subsequent NF-κB suppression (Sung et al., Int. Immunopharmacol., 2009, 9, 319–323). It also reduced IL-1β and iNOS mRNA expression in LPS-stimulated cells (Esatbeyoglu et al., 2016).

ε-Viniferin. ε-Viniferin suppresses NF-κB, COX-2, and PGE₂ production, though direct IC₅₀ values in macrophage models have not been isolated from mixture studies (comprehensive review, Naunyn-Schmiedeberg's Arch. Pharmacol., 2025).

Antimicrobial activity

α-Viniferin. Against methicillin-resistant Staphylococcus aureus (MRSA), α-viniferin showed a minimum inhibitory concentration (MIC) of 100 µg/mL. In combination with vancomycin, it exhibited an additive effect (fractional inhibitory concentration 0.5–2.0) against both MRSA strains tested (Basri et al., Pharmaceuticals, 2012, 5, 1032–1043). The trimer also showed significant activity against S. aureus and Escherichia coli and moderate activity against Salmonella paratyphi.

ε-Viniferin. Against MRSA, ε-viniferin showed a MIC of 400 µg/mL. More notably, it inhibited E. coli O157:H7 biofilm formation by 98% at 10 µg/mL and showed antibiofilm activity against Pseudomonas aeruginosa (Cho et al., J. Agric. Food Chem., 2013, 61, 7120; Lee et al., J. Nat. Prod., 2014, 77, 168–172).

Antiviral activity

Vitisin B. In a neuraminidase (NA) inhibition assay against influenza A virus, vitisin B achieved IC₅₀ values of 3.76 µM (H1N1), 37.7 µM (H3N2), and 32.6 µM (influenza B). Against an oseltamivir-resistant H1N1 strain, the NA IC₅₀ was 12.9 µM — the drug-resistant virus was insensitive to oseltamivir but remained susceptible to vitisin B. EC₅₀ values for viral replication inhibition in cell culture were 11.1 µM (H1N1), 7.1 µM (H3N2), and 11.7 µM (influenza B) (Kwon et al., J. Ethnopharmacol., 2023, 302, 115873). In BALB/c mice infected with H1N1 and treated orally at 20 mg/kg/day, vitisin B reduced mortality, attenuated body weight loss, and decreased viral load in lung tissue.

Vitisin A. A resveratrol tetramer was identified as a hepatitis C virus helicase inhibitor with antiviral activity in the low-micromolar range (Lee et al., Br. J. Pharmacol., 2016, 173, 191–211).

Cytotoxicity and metabolic activity

Vitisin A (R2-viniferin). Against hepatocellular carcinoma HepG2 cells, vitisin A achieved an IC₅₀ of 9.7 µM at 72 h, mediated through G2/M cell-cycle arrest and apoptosis with elevated Bax/Bcl-2 ratio. Activity has also been reported against glioblastoma and prostate cancer cell lines.

α-Viniferin. Oral administration at 20–40 mg/kg/day in high-fat diet-induced mice improved lipid and glucose homeostasis, with reductions in fasting blood glucose, HbA1c, and insulin resistance indices. Liver and renal biomarkers (blood urea nitrogen, creatinine, ALT, AST) also improved.

ε-Viniferin. ε-Viniferin and δ-viniferin (at 5–10 µM) protected scratched vascular endothelial cells from hydrogen peroxide-induced oxidative stress by elevating catalase protein levels.

Enzyme inhibition

Several resveratrol oligomers have shown direct enzyme inhibition with reported IC₅₀ values:

Sourcing

Sylverity supplies ε-viniferin (CAS 62218-08-0), δ-viniferin (CAS 71126-73-5), α-viniferin (CAS 62218-13-7), vitisin A (CAS 142449-89-6), and vitisin B (CAS 142449-90-9) as Research Use Only (RUO) reference standards for analytical and pharmacological research. Each lot ships with HPLC purity data and a Certificate of Analysis. Safety Data Sheet (SDS) is available on request.

Materials are for laboratory and analytical applications only. Not for human consumption, therapeutic use, or consumer resale.

For lot-specific documentation, quantity, or custom analytical requirements, contact the laboratory directly.